The Fall edition of eNews, DF/HCC's quarterly newsletter, has just been published
“I’ve been at this for 30 years and the last five years have been truly remarkable,” says Kenneth Anderson, MD (DFCI)
A highly anticipated new androgen synthesis inhibitor, abiraterone acetate, will be the subject of the first clinical study in men with localized, but high-risk, prostate cancer
Displaying results 1 to 5 out of 116
1
2
3
4
5
6
7
Next >
